4.6 Review

DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale

期刊

AMERICAN JOURNAL OF PSYCHIATRY
卷 170, 期 8, 页码 834-851

出版社

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2013.12060782

关键词

-

资金

  1. DETA Pharma
  2. Mundipharma
  3. Reckitt Benckiser Pharmaceuticals
  4. G.W. Pharmaceuticals
  5. Alkermes
  6. Braeburn Pharmaceuticals
  7. Reckitt/Benckiser
  8. Titan Pharmaceuticals
  9. U.S. World Meds
  10. SGS North America
  11. National Institute on Alcohol Abuse and Alcoholism [K05AA014223, U01AA018111]
  12. National Institute on Drug Abuse [R01DA018652]
  13. New York State Psychiatric Institute

向作者/读者索取更多资源

Since DSM-IV was published in 1994, its approach to substance use disorders has come under scrutiny. Strengths were identified (notably, reliability and validity of dependence), but concerns have also arisen. The DSM-5 Substance-Related Disorders Work Group considered these issues and recommended revisions for DSM-5. General concerns included whether to retain the division into two main disorders (dependence and abuse), whether substance use disorder criteria should be added or removed, and whether an appropriate substance use disorder severity indicator could be identified. Specific issues included possible addition of withdrawal syndrome's for several substances, alignment of nicotine criteria with those for other substances, addition of biomarkers, and inclusion of nonsubstance, behavioral addictions. This article presents the major issues and evidence considered by the work group, which included literature reviews and extensive new data analyses. The work group recommendations for DSM-5 revisions included combining abuse and dependence criteria into a single substance use disorder based on consistent findings from over 200,000 study participants, dropping legal problems and adding craving as criteria, adding cannabis and caffeine withdrawal syndromes, aligning tobacco use disorder criteria with other substance use disorders, and moving gambling disorders to the chapter formerly reserved for substance-related disorders. The proposed changes overcome many problems, while further studies will be needed to address issues for which less data were available.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据